Skip to main content

Arena Pharmaceuticals Inc

ARNADelisted Mar 11, 2022
Industry
Pharmaceutical Preparations
SEC CIK
0001080709

Arena Pharmaceuticals Inc was delisted on Mar 11, 2022; its insiders filed their last Form 4 on Mar 11, 2022; 317 institutions reported holding it in 13F filings for Q4 2021, worth $4.87B in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Arena Pharmaceuticals Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Arena Pharmaceuticals Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Arena Pharmaceuticals Inc
NameTitleLast reported holdingLast filingFilings, past year
Fetzer OliverDirector0Mar 11, 20220
Nova Tina SusanDirector0Mar 11, 20220
Gallahue KieranDirector0Mar 11, 20220
Neil Garry ArthurDirector0Mar 11, 20220
Munshi AmitPresident and CEO0Mar 11, 20220
Stelzer LaurieEVP & Chief Financial Officer0Mar 11, 20220
Dallas Jayson Donald AlexanderDirector0Mar 11, 20220
Aurentz VincentExecutive VP and CBO0Mar 11, 20220
Jarrett JenniferDirector0Mar 11, 20220
Knobil KatharineDirector0Mar 11, 20220
Lisicki RobertEVP, Chief Commercial Officer0Mar 11, 20220
Schmidt JoanEVP, General Counsel & Sec0Mar 11, 20220
Ouzren NawalDirector0Mar 11, 20220
Schoch Steven JDirector0Mar 11, 20220
Manion Douglas J.EVP Research & Development0Mar 11, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 17, 2021 (view filing)Aug 161 dayMunshi AmitPresident and CEOPPurchase+1.00K$48.19+$48.2K+2.6%39.5K after
Aug 13, 2021 (view filing)Aug 121 dayMunshi AmitPresident and CEOPPurchase+1.00K$50.41+$50.4K+2.7%38.5K after
Aug 11, 2021 (view filing)Aug 101 dayMunshi AmitPresident and CEOPPurchase+1.00K$52.92+$52.9K+2.7%37.5K after
Aug 5, 2021 (view filing)Aug 32 daysLisicki RobertEVP, Chief Commercial OfficerSSale−17.5K$60.08−$1.05M−52.1%16.1K after2 lots